SCHEMBL19173641

SCHEMBL19173641

CCC1CC(=NOC)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10327174 0.83 NOS3 (0.37)
SCHEMBL12949146 0.77 ALDH1A1 (0.32)
SCHEMBL18727433 0.71
SCHEMBL14550074 0.69 HSD11B1 (0.31)
SCHEMBL7893573 0.67 NOS3 (0.31)
SCHEMBL4752634 0.67 HSD11B1 (0.31)
SCHEMBL30857799 0.65 CCR5 (0.35)
SCHEMBL7808288 0.64 HSD11B1 (0.45)
SCHEMBL5074095 0.64 HSD11B1 (0.33)
SCHEMBL30798149 0.64 HSD11B1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9724354-B2 Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-08-08 US disclosed
US-20170209448-A1 TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS INTELLIKINE LLC 2017-07-27 US disclosed